Shanghai Fosun Pharmaceutical (600196.SH): HLX18 approved for Phase I clinical trial for treatment of various solid tumors.

Fosun Pharma (600196.SH) announced that its controlling subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd. and its subsidiary (collectively "Fuhong Hanlin"), have received approval from the National Medical Products Administration to conduct phase I clinical trials for HLX18 (a recombinant anti-PD-1 humanized monoclonal antibody injection) for the treatment of multiple solid tumors. Fuhong Hanlin plans to conduct relevant clinical studies for this drug in China as soon as the conditions are met.